The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas.

TitleThe potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas.
Publication TypeJournal Article
Year of Publication2013
AuthorsBacon KM, Hotez PJ, Kruchten SD, Kamhawi S, Bottazzi MElena, Valenzuela JG, Lee BY
Date Published2013 Jan 7
KeywordsAmericas, Computer Simulation, Costs and Cost Analysis, Endemic Diseases, Humans, Leishmaniasis Vaccines, Leishmaniasis, Cutaneous

Cutaneous leishmaniasis (CL) and its associated complications, including mucocutaneous leishmaniasis (MCL) and diffuse CL (DCL) have emerged as important neglected tropical diseases in Latin America, especially in areas associated with human migration, conflict, and recent deforestation. Because of the limitations of current chemotherapeutic approaches to CL, MCL, and DCL, several prototype vaccines are in different states of product and clinical development. We constructed and utilized a Markov decision analytic computer model to evaluate the potential economic value of a preventative CL vaccine in seven countries in Latin America: Bolivia, Brazil, Colombia, Ecuador, Mexico, Peru, and Venezuela. The results indicated that even a vaccine with a relatively short duration of protection and modest efficacy could be recommended for use in targeted locations, as it could prevent a substantial number of cases at low-cost and potentially even result in cost savings. If the population in the seven countries were vaccinated using a vaccine that provides at least 10 years of protection, an estimated 41,000-144,784 CL cases could be averted, each at a cost less than the cost of current recommended treatments. Further, even a vaccine providing as little as five years duration of protection with as little as 50% efficacy remains cost-effective compared with chemotherapy; additional scenarios resembling epidemic settings such as the one that occurred in Chaparral, Colombia in 2004 demonstrate important economic benefits.

Alternate JournalVaccine
PubMed ID23176979
PubMed Central IDPMC3763201
Grant List5U54GM088491-02 / GM / NIGMS NIH HHS / United States
U54 GM088491 / GM / NIGMS NIH HHS / United States
Z99 AI999999 / AI / NIAID NIH HHS / United States
Publication Categories: